STOCK TITAN
  1. Home
  2. News
  3. VXRT

Vaxart Inc - VXRT STOCK NEWS

Welcome to our dedicated news page for Vaxart (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vaxart's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vaxart's position in the market.

News
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
Rhea-AI Summary
Vaxart, Inc. (VXRT) announced that Dr. Sean Tucker will present at the World Vaccine Congress Washington 2024. The presentation focuses on oral tablet vaccination to enhance existing vaccines and block transmission. The event is scheduled for April 3, 2024, at 3:10 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
conferences
-
News
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Vaxart, Inc. announced equity awards for its new President and CEO, Steven Lo, including 1,000,000 stock options and 250,000 restricted stock units. The options vest over time, and the awards were granted under an inducement award plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
none
-
News
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
Rhea-AI Summary
Vaxart, Inc. announces significant progress in preparing for a Phase 2b study evaluating its oral pill XBB COVID-19 vaccine, appoints Steven Lo as President and CEO, and reports financial results for full year 2023. The company received a $9.27 million contract for a Phase 2b clinical study against an approved mRNA vaccine. Vaxart also published preclinical data showing immune responses against multiple SARS-CoV-2 variants. In the norovirus vaccine space, the company completed enrollment in a Phase 1 study in lactating mothers and expects topline data in mid-2024. Financially, Vaxart reported $39.7 million in cash and investments as of December 31, 2023, with a net loss of $82.5 million for 2023 compared to $107.8 million in 2022. Revenue for 2023 was $7.4 million, primarily from grants and royalties. Research and development expenses decreased to $68.1 million in 2023, while general and administrative expenses were $22.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
earnings
News
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
Rhea-AI Summary
Vaxart, Inc. (NASDAQ: VXRT) announces a business update and financial results for the full year ending December 31, 2023. The senior management team will host a conference call on March 14, 2024, at 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
conferences earnings
-
News
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
Rhea-AI Summary
Vaxart, Inc. appoints Steven Lo as President and CEO, with Michael J. Finney, Ph.D. continuing as Chairman of the Board. The new CEO brings over 25 years of experience in the biopharma industry and aims to lead the Company's transformational oral vaccine platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
management
-
News
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
Rhea-AI Summary
Vaxart, Inc. announces promising preclinical non-human primate data demonstrating the potential of its COVID-19 vaccine to protect against multiple SARS-CoV-2 variants of concern. The data support the vaccine platform's potential to stimulate potent mucosal cross-reactive IgA responses to multiple VOCs and reduce viral transmission. Vaxart's preparation for a Phase 2b trial of its COVID-19 XBB vaccine candidate is supported by a recent grant awarded by the United States Biomedical Advanced Research and Development Authority (BARDA). The study published in Vaccines showed that all three vaccines elicited strong cross-reactive systemic immunity and robust cross-reactive nasal and lung IgA following mucosal vaccination, as well as reduced viral replication and infectious particle shedding in immunized animals after challenge with the beta variant of SARS-CoV-2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
clinical trial
News
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Rhea-AI Summary
Vaxart, Inc. announced that it has been awarded $9.27 million by BARDA to fund preparation for a Phase 2b clinical study evaluating its oral pill XBB COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The study is part of the Project NextGen, a $5 billion initiative by the U.S. Department of Health and Human Services to develop innovative vaccines and therapeutics for COVID-19. Vaxart's CEO, Dr. Michael Finney, expressed excitement over the potential of their oral pill vaccine platform to revolutionize pandemic fighting and vaccination against infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags
clinical trial covid-19
-
News
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
Rhea-AI Summary
Vaxart, Inc. (VXRT) has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering price of $0.65 per share, generating approximately $10.0 million in gross proceeds. The net proceeds will be used for general corporate purposes, including working capital, operating expenses, and capital expenditures. The company aims to continue advancing its oral pill vaccine platform with the goal of bringing to market oral pill vaccines that carry significant public health benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.57%
Tags
offering
-
News
Vaxart, Inc. Announces Management Change
Rhea-AI Summary
Vaxart, Inc. (Nasdaq: VXRT) announced the resignation of Andrei Floroiu, President and CEO, and the appointment of Michael J. Finney, Ph.D. as the Interim CEO. Dr. Finney will lead the management team through the transition while the company conducts a search for a permanent CEO. Mr. Floroiu expressed confidence in Dr. Finney's ability to advance Vaxart's oral vaccine platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.57%
Tags
none
News
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
Rhea-AI Summary
Vaxart, Inc. (Nasdaq: VXRT) has completed enrollment and dosing in the Phase 1 clinical trial for its oral pill bivalent norovirus vaccine candidate focused on lactating mothers. The company aims to report topline data by the end of 2024. Norovirus sickens approximately 21 million people in the United States annually, with 15% of children under age 5 contracting the virus. The annual disease burden from norovirus is $10.6 billion in the U.S. alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Stock VXRT logo
Vaxart Inc

Nasdaq:VXRT

VXRT Rankings

#3975 Ranked by Market Cap
#4907 Ranked by Stock Gains
N/A Ranked by Dividends

VXRT Stock Data

158.23M
156.96M
0.97%
18.13%
9.89%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
South San Francisco

About VXRT

since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.